Molecular mechanisms of nicotine-induced bladder cancer

Journal of Experimental and Clinical Medicine

Volumn 3, Issue 6, 2011, Pages 252-256

  Chen, Rong Jane ^a   Ho, Yuan Soon ^b   Wu, Chih Hsiung ^c,d   Wang, Ying Jan ^a,e  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Shuang Ho Hospital   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Bladder cancer; Chemoprevention; Chemoresistance; Cigarette smoke; Nicotine; Pterostilbene

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETULIC ACID; CIGARETTE SMOKE; CURCUMIN; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; PTEROSTILBENE; RESVERATROL; SALIDROSIDE; STAT3 PROTEIN; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOPHAGY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER RISK; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CIGARETTE SMOKING; DNA BINDING; DRUG DESIGN; DRUG TARGETING; HUMAN; NECROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; URINE;

EID: 83555176307     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2011.10.001     Document Type: Review

References (71)

1. IARC Cancer, tobacco smoking and tobacco smoke. IARC monographs on the evaluation of the carcinogenic risks of chemicals to humans 2004, IARC, Lyon, France, p. 83.
2. Alberg A.J., Hebert J.R. Cigarette smoking and bladder cancer: a new twist in an old saga?. J Natl Cancer Inst 2009, 101:1525-1526.
3. Skipper P.L., Tannenbaum S.R., Ross R.K., Yu M.C. Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2003, 12:503-507.
4. Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs 2002, 62(Suppl. 2):1-9.
5. Oh W.K., Manola J., Renshaw A.A., Brodkin D., Loughlin K.R., Richie J.P., Shapiro C.L., et al. Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. Urology 2000, 55:31-35.
6. Fleshner N., Garland J., Moadel A., Herr H., Ostroff J., Trambert R., O'Sullivan M., et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 1999, 86:2337-2345.
7. Marshak G., Brenner B., Shvero J., Shapira J., Ophir D., Hochman I., Sulkes A., et al. Prognostic factors for local control of early glottic cancer: the Rabin medical center retrospective study on 207 patients. Int J Radiat Oncol Biol Phys 1999, 43:1009-1013.
8. Browman G.P., Wong G., Hodson I., Sathya J., Russell R., McAlpine L., Skingley P., et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993, 328:159-163.
9. Kuper H., Adami H.O., Boffetta P. Tobacco use, cancer causation and public health impact. J Intern Med 2002, 251:455-466.
10. Jiang X., Yuan J.M., Skipper P.L., Tannenbaum S.R., Yu M.C. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles county. Cancer Res 2007, 67:7540-7545.
11. Zeegers M.P.A., Goldbohm R.A., van den Brandt P.A. A prospective study on active and environmental tobacco smoking and bladder cancer risk. Cancer Causes & Control 2002, 13:83-90.
12. Ross R.K., Jones P.A., Yu M.C. Bladder cancer epidemiology and pathogenesis. Semin Oncol 1996, 23:536-545.
13. Cohen S.M., Purtilo D.T., Ellwein L.B. Ideas in pathology. Pivotal role of increased cell proliferation in human carcinogenesis. Mod Pathol 1991, 4:371-382.
14. Heeschen C., Jang J.J., Weis M., Pathak A., Kaji S., Hu R.S., Tsao P.S., et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001, 7:833-839.
15. Xin M., Deng X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 2005, 280:10781-10789.
16. Chen R.J., Ho Y.S., Guo H.R., Wang Y.J. Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. Toxicol Sci 2010, 115:118-130.
17. Heinrich J., Holscher B., Seiwert M., Carty C., Merkel G., Schulz C. Nicotine and cotinine in adults' urine: the German environmental survey 1998. J Expo Anal Environ Epidemiol 2004, 15:74-80.
18. Pontieri F.E., Tanda G., Orzi F., Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382:255-257.
19. Lam D.C., Girard L., Ramirez R., Chau W.S., Suen W.S., Sheridan S., Tin V.P., et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 2007, 67:4638-4647.
20. Gotti C., Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 2004, 74:363-396.
21. De Biasi M., Nigro F., Xu W. Nicotinic acetylcholine receptors in the autonomic control of bladder function. Eur J Pharmacol 2000, 393:137-140.
22. Wada T., Naito M., Kenmochi H., Tsuneki H., Sasaoka T. Chronic nicotine exposure enhances insulin-induced mitogenic signaling via up-regulation of alpha7 nicotinic receptors in isolated rat aortic smooth muscle cells. Endocrinology 2007, 148:790-799.
23. Wong H.P., Yu L., Lam E.K., Tai E.K., Wu W.K., Cho C.H. Nicotine promotes colon tumor growth and angiogenesis through {beta}-adrenergic activation. Toxicol Sci 2007, 97:279-287.
24. Laag E., Majidi M., Cekanova M., Masi T., Takahashi T., Schuller H. NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int J Cancer 2006, 119:1547-1552.
25. Tournier J.M., Birembaut P. Nicotinic acetylcholine receptors and predisposition to lung cancer. Curr Opin Oncol 2010, 23:83-87.
26. Egleton R.D., Brown K.C., Dasgupta P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends Pharmacol Sci 2008, 29:151-158.
27. West K.A., Linnoila I.R., Belinsky S.A., Harris C.C., Dennis P.A. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res 2004, 64:446-451.
28. Bose C., Zhang H., Udupa K.B., Chowdhury P. Activation of p-ERK1/2 by nicotine in pancreatic tumor cell line AR42J: effects on proliferation and secretion. Am J Physiol-Gastroint Liver Physiol 2005, 289:G929-G934.
29. Chowdhury P., Bose C., Udupa K.B. Nicotine-induced proliferation of isolated rat pancreatic acinar cells: effect on cell signalling and function. Cell Prolif 2007, 40:125-141.
30. West K.A., Brognard J., Clark A.S., Linnoila I.R., Yang X., Swain S.M., Harris C., et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003, 111:81-90.
31. Shin V.Y., Wu W.K., Chu K.M., Koo M.W., Wong H.P., Lam E.K., Tai E.K., et al. Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. Toxicol Sci 2007, 96:21-29.
32. Trombino S., Cesario A., Margaritora S., Granone P., Motta G., Falugi C., Russo P. Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res 2004, 64:135-145.
33. Lee C.H., Huang C.S., Chen C.S., Tu S.H., Wang Y.J., Chang Y.J., Tam K.W., et al. Overexpression and activation of the alpha9-nicotinic receptor during tumorigenesis in human breast epithelial cells. J Natl Cancer Inst 2010, 102:1322-1335.
34. Chernyavsky A.I., Arredondo J., Vetter D.E., Grando S.A. Central role of alpha9 acetylcholine receptor in coordinating keratinocyte adhesion and motility at the initiation of epithelialization. Exp Cell Res 2007, 313:3542-3555.
35. Nakajima M., Yokoi T. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 2005, 20:227-235.
36. Carty C.S., Huribal M., Marsan B.U., Ricotta J.J., Dryjski M. Nicotine and its metabolite cotinine are mitogenic for human vascular smooth muscle cells. J Vasc Surg 1997, 25:682-688.
37. Chen R.J., Ho Y.S., Guo H.R., Wang Y.J. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci 2008, 104:283-293.
38. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002, 109:1139-1142.
39. Campbell C.L., Guardiani R., Ollari C., Nelson B.E., Quesenberry P.J., Savarese T.M. Interleukin-11 receptor expression in primary ovarian carcinomas. Gynecol Oncol 2001, 80:121-127.
40. Itoh M., Murata T., Suzuki T., Shindoh M., Nakajima K., Imai K., Yoshida K. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 2006, 25:1195-1204.
41. Gago-Dominguez M., Jiang X., Conti D.V., Castelao J.E., Stern M.C., Cortessis V.K., Pike M.C., et al. Genetic variations on chromosomes 5p15 and 15q25 and bladder cancer risk: findings from the Los Angeles-Shanghai bladder case-control study. Carcinogenesis 2011, 32:197-202.
42. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., Manolescu A., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452:638-642.
43. Ouerhani, Rouissi K., Kourda N., Marrakchi R., Bougatef K., Riadh Ben Slama M., Sfaxi, et al. Combined analysis of smoking, TP53, and FGFR3 mutations in Tunisian patients with invasive and superficial high-grade bladder tumors. Cancer Invest 2009, 27:998-1007.
44. Moonen P.M., van Balken-Ory B., Kiemeney L.A., Schalken J.A., Witjes J.A. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 2007, 177:80-83.
45. LaRue H., Allard P., Simoneau M., Normand C., Pfister C., Moore L., Meyer F., et al. P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis 2000, 21:101-106.
46. Kelsey K.T., Hirao T., Hirao S., Devi-Ashok T., Nelson H.H., Andrew A., Colt J., et al. TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. Int J Cancer 2005, 117:370-375.
47. Puliyappadamba V.T., Cheriyan V.T., Thulasidasan A.K., Bava S.V., Vinod B.S., Prabhu P.R., Varghese, et al. Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol Cancer 2010, 9:220.
48. Liu D., Pan F., Li B., Han X., Li W., Shi Y., Pang Z., et al. Intervention of nicotine on MNU-induced bladder cancer in rats. J Huazhong Univ Sci Technolog Med Sci 2011, 31:103-106.
49. Xu J., Huang H., Pan C., Zhang B., Liu X., Zhang L. Nicotine inhibits apoptosis induced by cisplatin in human oral cancer cells. Int J Oral Maxillofac Surg 2007, 36:739-744.
50. Mai H., May W.S., Gao F., Jin Z., Deng X. A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 2003, 278:1886-1891.
51. Dasgupta P., Chellappan S.P. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 2006, 5:2324-2328.
52. Zhao R., Chen H., Sharp B.M. Nicotine-induced norepinephrine release in hypothalamic paraventricular nucleus and amygdala is mediated by N-methyl-D-aspartate receptors and nitric oxide in the nucleus tractus solitarius. J Pharmacol Exp Ther 2007, 320:837-844.
53. Lu Y., Fukuyama S., Yoshida R., Kobayashi T., Saeki K., Shiraishi H., Yoshimura A., et al. Loss of SOCS3 gene expression converts STAT3 function from anti-apoptotic to pro-apoptotic. J Biol Chem 2006, 281:36683-36690.
54. Aggarwal B.B., Sethi G., Ahn K.S., Sandur S.K., Pandey M.K., Kunnumakkara A.B., Sung B., et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006, 1091:151-169.
55. Duan Z., Foster R., Bell D.A., Mahoney J., Wolak K., Vaidya A., Hampel C., et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006, 12:5055-5063.
56. Rimando A.M., Kalt W., Magee J.B., Dewey J., Ballington J.R. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem 2004, 52:4713-4719.
57. Rimando A.M., Cuendet M., Desmarchelier C., Mehta R.G., Pezzuto J.M., Duke S.O. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem 2002, 50:3453-3457.
58. Chiou Y.S., Tsai M.L., Nagabhushanam K., Wang Y.J., Wu C.H., Ho C.T., Pan M.H. Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. J Agric Food Chem 2011, 59:2725-2733.
59. Stivala L.A., Savio M., Carafoli F., Perucca P., Bianchi L., Maga G., Forti L., et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 2001, 276:22586-22594.
60. Ferrer P., Asensi M., Segarra R., Ortega A., Benlloch M., Obrador E., Varea M.T., et al. Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia 2005, 7:37-47.
61. Remsberg C.M., Yanez J.A., Ohgami Y., Vega-Villa K.R., Rimando A.M., Davies N.M. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother Res 2008, 22:169-179.
62. Chiou Y.S., Tsai M.L., Wang Y.J., Cheng A.C., Lai W.M., Badmaev V., Pan M.H. Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice. J Agric Food Chem 2010, 58:8833-8841.
63. Pan M.H., Chiou Y.S., Chen W.J., Wang J.M., Badmaev V., Ho C.T. Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. Carcinogenesis 2009, 30:1234-1242.
64. Liu Z., Li X., Simoneau A.R., Jafari M., Zi X. Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy. Mol Carcinog 2011, 10.1002/mc.20780.
65. Chadalapaka G., Jutooru I., Burghardt R., Safe S. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 2010, 8:739-750.
66. Opipari A.W., Tan L., Boitano A.E., Sorenson D.R., Aurora A., Liu J.R. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 2004, 64:696-703.
67. Scarlatti F., Maffei R., Beau I., Codogno P., Ghidoni R. Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ 2008, 15:1318-1329.
68. Ho Y.S., Lee C.H., Wu C.H. α9-nicotinic acetylcholine receptor serves as a molecular target for breast cancer therapy. J Exp Clin Med 2011, 3:246-251.
69. Hung C.S., Pung Y.J., Wei P.L., Lee C.H., Su H.Y., Ho Y.S., Wu C.H., et al. The Alpha9 nicotinic acetylcholine receptor is the key mediator in nicotine-enhanced cancer metastasis in breast cancer cells. J Exp Clin Med 2011, 3:283-292.
70. Wei P.L., Lin S.Y., Chang Y.J. Cigarette smoking and colorectal cancer: from epidemiology to bench. J Exp Clin Med 2011, 3:257-261.
71. Lai C.S., Pan M.H. Chemopreventive effects of natural dietary compounds on smoking-inducedtumorigenesis. J Exp Clin Med 2011, 3:262-271.